Should I buy or sell BioLineRx stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLRX shares. View BLRX analyst ratings or view top-rated stocks .

What is BioLineRx's stock price target for 2024?

1 brokers have issued twelve-month price objectives for BioLineRx's shares. Their BLRX share price targets range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next year. This suggests a possible upside of 3,230.7% from the stock's current price. View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts .

How have BLRX shares performed in 2024?

BioLineRx's stock was trading at $1.57 at the start of the year. Since then, BLRX shares have decreased by 59.8% and is now trading at $0.6305. View the best growth stocks for 2024 here .

Are investors shorting BioLineRx?

BioLineRx saw a increase in short interest in March. As of March 31st, there was short interest totaling 591,500 shares, an increase of 82.2% from the March 15th total of 324,700 shares. Based on an average daily trading volume, of 377,300 shares, the days-to-cover ratio is presently 1.6 days. View BioLineRx's Short Interest .

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our BLRX earnings forecast .

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) issued its earnings results on Thursday, March, 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. The biotechnology company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same quarter last year, the company earned ($0.09) EPS.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Zosano Pharma (ZSAN) , KushCo (KSHB) , Aeterna Zentaris (AEZS) , CNBX Pharmaceuticals (CNBX) , Pennsylvania Real Estate Investment Trust (PEI) , Savara (SVRA) , Bionano Genomics (BNGO) and Gran Tierra Energy (GTE) .

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BLRX

BioLineRx (BLRX) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free BLRX Stock Alerts

$0.64

0.00 (0.00%)

(As of 04/16/2024 ET)

Compare

Today's Range: $0.62
▼
$0.67
50-Day Range: $0.64
▼
$1.38
52-Week Range: $0.62
▼
$2.53

Volume: 253,023 shs
Average Volume: 399,727 shs
Market Capitalization: $51.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Get BioLineRx alerts:

BioLineRx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3,230.7% Upside
$21.00 Price Target
Short Interest: Healthy
0.74% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.03) to ($0.93) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.65 out of 5 stars

Medical Sector

687th out of 930 stocks

Biotechnology Industry

8th out of 22 stocks

3.5

Analyst's Opinion

Consensus Rating
BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
BioLineRx has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.74% of the outstanding shares of BioLineRx have been sold short.
Short Interest Ratio / Days to Cover
BioLineRx has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioLineRx has recently increased by 82.17%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioLineRx does not currently pay a dividend.
Dividend Growth
BioLineRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLRX.

2.4

News and Social Media Coverage

News Sentiment
BioLineRx has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for BioLineRx this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
11 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioLineRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.10% of the stock of BioLineRx is held by insiders.
Percentage Held by Institutions
Only 1.56% of the stock of BioLineRx is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioLineRx are expected to grow in the coming year, from ($1.03) to ($0.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioLineRx is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioLineRx is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioLineRx has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About BioLineRx Stock (NASDAQ:BLRX)

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

BLRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLRX Stock News Headlines

April 14, 2024 | americanbankingnews.com

BioLineRx (NASDAQ:BLRX) Raised to Sell at StockNews.com

April 11, 2024 | investing.com

BioLineRx secures $20 million in BlackRock financing

April 16, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 10, 2024 | finance.yahoo.com

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

April 10, 2024 | prnewswire.com

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

April 1, 2024 | prnewswire.com

BioLineRx Announces $6 Million Registered Direct Offering

March 28, 2024 | finanznachrichten.de

BioLineRx Ltd.: BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

March 27, 2024 | finance.yahoo.com

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript

April 16, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 27, 2024 | finance.yahoo.com

BLRX: First Aphexda Sales Recognized

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst Optimism

March 26, 2024 | prnewswire.com

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

March 20, 2024 | prnewswire.com

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

March 4, 2024 | finance.yahoo.com

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

March 1, 2024 | investing.com

BioLineRx begins phase 2 trial for pancreatic cancer treatment

March 1, 2024 | finance.yahoo.com

BLRX Mar 2024 1.000 call

February 28, 2024 | prnewswire.com

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

February 26, 2024 | finance.yahoo.com

BLRX: Poster Presentations

February 25, 2024 | investorplace.com

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

February 23, 2024 | ca.finance.yahoo.com

BLRX May 2024 1.000 put

February 16, 2024 | finance.yahoo.com

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

February 16, 2024 | prnewswire.com

December 21, 2023 | finance.yahoo.com

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

December 4, 2023 | seekingalpha.com

BioLineRx: Still A Buy, With Some Questions

December 3, 2023 | seekingalpha.com

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges

November 21, 2023 | insidermonkey.com

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript

November 21, 2023 | markets.businessinsider.com

Bioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future Growth

See More Headlines

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:BLRX
CUSIP: N/A
CIK: 1498403
Web: www.biolinerx.com
Phone: (728) 642-9100
Fax: 972-8642-9101
Employees: 79
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.00
High Stock Price Target: $21.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +3,230.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-60,610,000.00
Net Margins: N/A
Pretax Margin: -1,262.79%
Return on Equity: -280.21%
Return on Assets: -99.22%

Debt

Debt-to-Equity Ratio: 0.50
Current Ratio: 1.53
Quick Ratio: 1.47

Sales & Book Value

Annual Sales: $4.80 million
Price / Sales: 10.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.18 per share
Price / Book: 3.50

Miscellaneous

Outstanding Shares: 79,940,000
Free Float: 79,060,000
Market Cap: $50.40 million
Optionable: Optionable
Beta: 1.38

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Philip A. Serlin CPA (Age 64)
M.B.A., CPA, MBA, Chief Executive Officer
Comp: $598k
Ms. Mali Zeevi CPA (Age 48)
CPA, Chief Financial Officer
Comp: $374k
Dr. Ella Sorani Ph.D. (Age 56)
Chief Development Officer
Comp: $452k
Ms. Holly W. May M.B.A. (Age 62)
President of BioLineRx USA
Comp: $710k
Mr. John Lacey
Head of Corporate Communications & Investor Relations
Ms. Tsipi Keren-Lehrer B.Sc.
L.L.B., Head of BD & Strategic Advisor
Mr. Raziel Fried
Treasurer & Budgetary Control Director

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings or view top-rated stocks.
What is BioLineRx's stock price target for 2024?: 1 brokers have issued twelve-month price objectives for BioLineRx's shares. Their BLRX share price targets range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next year. This suggests a possible upside of 3,230.7% from the stock's current price.
View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts.
How have BLRX shares performed in 2024?: BioLineRx's stock was trading at $1.57 at the start of the year. Since then, BLRX shares have decreased by 59.8% and is now trading at $0.6305.
View the best growth stocks for 2024 here.
Are investors shorting BioLineRx?: BioLineRx saw a increase in short interest in March. As of March 31st, there was short interest totaling 591,500 shares, an increase of 82.2% from the March 15th total of 324,700 shares. Based on an average daily trading volume, of 377,300 shares, the days-to-cover ratio is presently 1.6 days.
View BioLineRx's Short Interest.

When is BioLineRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our BLRX earnings forecast.
How were BioLineRx's earnings last quarter?: BioLineRx Ltd. (NASDAQ:BLRX) issued its earnings results on Thursday, March, 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. The biotechnology company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same quarter last year, the company earned ($0.09) EPS.
What other stocks do shareholders of BioLineRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).
How do I buy shares of BioLineRx?: Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial